

From: Clegg, Patsy M SCC-CHSE-PC <patsy.clegg@shell.com>
Sent: Tuesday, April 27, 2004 6:50 PM (GMT)
To: Cagen, Stuart Z SCC-HSE <stuart.cagen@shell.com>; Colletti, Sarah J SCC-CSEA <sarah.colletti@shell.com>; Iannarone, Lauren B SCC-CSEA <Lauren.Iannarone@shell.com>; Samuel, Tarita B SCC-CCFF-FN <tarita.samuel@shell.com>; Sullivan, Nancy E SCC-CBAR <nancy.sullivan@shell.com>; Tholstrup, Susan C SCC-HSE <susan.tholstrup@shell.com>; Tsai, Shan SP SHLOIL-SHLOIL-HE <Shan.Tsai@shell.com>
Cc: Williams, Elizabeth J SCCA-HSE <elizabeth.williams@shell.com>
Subject: Shanghai Health Study - Notes from recent Oversight Committee Meeting

The SHS Oversight Committee (OC) met in Houston April 21-22. Decisions made at the meeting include:

- Approval of the 4Q03 financial report. Study is on budget. 1Q04 financial report to be reviewed May 14.
- Decision to not invoice sponsors in 04. Study has enough money to fund through 04 and well into 05. Decision on 05 by June 15.
- Outreach plan for 3rd party stakeholders outlined. Significant event for planning is the Benzene Symposium in Munich in October where the investigators will be presenting papers.
- Consortium/API contract amendment terms agreed:
 - Payment of committed funds will be decided by the OC; not put in the contract. Invoice plan due by June 15 for each year.
 - Shares will be allocated based on 1 share per \$500K contribution. Shell will have 8 of 41 shares. Shell voted against this option based on guidance from management to vote for option 1 which added 1 share to each company that provided additional funding.

I would be happy to discuss or answer any questions.

Regards,

Patsy

Patsy Clegg
Product Steward
Shell Chemical LP
One Shell Plaza, 910 Louisiana, Houston, TX 77002-4916
Tel: +1 713 241 2521 **Fax:** 3325
Email: patsy.clegg@shell.com
Internet: <http://www.shell.com/chemicals>